Prelude Therapeutics (PRLD) Stock Forecast & Price Target

$1.05 0.00 (0.00%)

(As of 11/29/2024 ET)

Prelude Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 4 Analyst Ratings

Sell
2

Hold
0

Buy
2

Based on 4 Wall Street analysts who have issued ratings for Prelude Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 4 analysts, 2 have given a sell rating, and 2 have given a buy rating for PRLD.

Consensus Price Target

$4.75
352.38% Upside

According to the 4 analysts' twelve-month price targets for Prelude Therapeutics, the average price target is $4.75. The highest price target for PRLD is $7.00, while the lowest price target for PRLD is $3.00. The average price target represents a forecasted upside of 352.38% from the current price of $1.05.

Get the Latest News and Ratings for PRLD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Prelude Therapeutics and its competitors.

PRLD Analyst Ratings Over Time

Type	Current Forecast 12/1/23 to 11/30/24	1 Month Ago 11/1/23 to 10/31/24	3 Months Ago 9/2/23 to 9/1/24	1 Year Ago 12/1/22 to 12/1/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$4.75	$4.75	$4.75	$6.67
Forecasted Upside	352.38% Upside	295.83% Upside	-8.65% Downside	106.72% Upside
Consensus Rating	Hold	Hold	Sell	Hold

***TODAY ONLY*** The winner of the next crypto bull run? (Ad)

Donald Trump is about to send crypto "to the moon." Crypto expert Juan Villaverde says this could be the start of the greatest bull market in crypto history. Now you can learn how to play it with this exclusive offer. And it isn't Bitcoin.

Now you can learn what it is via this exclusive, limited time offer.

PRLD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PRLD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Prelude Therapeutics Stock vs. The Competition

Type	Prelude Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	352.38% Upside	25,347.86% Upside	6.51% Upside
News Sentiment Rating	Neutral News See Recent PRLD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/8/2024	HC Wainwright 2 of 5 stars	R. Burns Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00	+316.66%
9/16/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Outperform	$7.00 ➝ $7.00	+171.32%
6/20/2024	Barclays 3 of 5 stars	P. Lawson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$3.00	-22.48%
12/19/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Equal Weight ➝ Underweight	$10.00 ➝ $4.00	-8.47%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:56 PM ET.

PRLD Forecast - Frequently Asked Questions

: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Prelude Therapeutics is $4.75, with a high forecast of $7.00 and a low forecast of $3.00.
: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last year. There are currently 2 sell ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRLD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRLD, but not buy additional shares or sell existing shares.
: According to analysts, Prelude Therapeutics's stock has a predicted upside of 352.38% based on their 12-month stock forecasts.
: Over the previous 90 days, Prelude Therapeutics's stock had 1 upgrade by analysts.
: Prelude Therapeutics has been rated by research analysts at HC Wainwright, and JMP Securities in the past 90 days.
: Analysts like Prelude Therapeutics less than other "medical" companies. The consensus rating for Prelude Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PRLD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

***TODAY ONLY*** The winner of the next crypto bull run? (Ad)

Now you can learn what it is via this exclusive, limited time offer.

This page (NASDAQ:PRLD) was last updated on 11/30/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prelude Therapeutics (PRLD) Stock Forecast & Price Target